Both dupilumab and mepolizumab were originally approved for asthma but were subsequently studied in patients with COPD who continue to experience symptoms and moderate-to-severe exacerbations despite ...

The European approval for GSK's depemokimab joins recently announced data on vaccine efficacy and progress on 4-month viral treatments.

Ischaemic heart disease killed more people than any other condition on the planet in 2021, holding a grim title it has ...

Ventavis® is an established inhaled prostacyclin analogue for the treatment of primary pulmonary hypertensionAcquisition reinforces Essential Pharma’s mission to serve the needs of rare disease ...

Patent ductus arteriosus is a congenital heart defect that requires timely surgery.

As part of the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI Bio, discussed important insights from the Company’s recently reported additional positive Phase 2a data ...

OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or “the Company”), the world leader in listeria-based cancer ...

Key points A 39-year-old woman with a known history of antiphospholipid syndrome (APS) presented to the emergency department with acute shortness of breath, pleuritic chest pain, and presyncope. On ...

UCLA researchers have developed a lipid nanoparticle-based gene-editing approach capable of inserting an entire healthy gene into human airway cells, restoring key biological function in a laboratory ...

Objectives Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic autoimmune disease where infections ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved a new, simplified monthly dosing schedule for Johnson & Johnson’s JNJ Rybrevant Faspro (amivantamab and hyaluronidase-lpuj). When ...

The FDA has approved a new, simplified monthly subcutaneous (SC) dosing schedule for amivantamab and hyaluronidase-lpuj (Rybrevant Faspro; Johnson & Johnson) for the treatment of patients with ...